Bausch Health Companies Inc (TSE:BHC) – Equities research analysts at Jefferies Financial Group upped their FY2019 earnings estimates for shares of Bausch Health Companies in a note issued to investors on Friday, September 20th. Jefferies Financial Group analyst D. Steinberg now expects that the company will earn $5.45 per share for the year, up from their previous forecast of $5.36. Jefferies Financial Group also issued estimates for Bausch Health Companies’ FY2020 earnings at $6.05 EPS, FY2021 earnings at $6.66 EPS, FY2022 earnings at $7.10 EPS and FY2023 earnings at $7.69 EPS.
Separately, Barclays decreased their price objective on shares of Bausch Health Companies from C$31.00 to C$28.00 in a research note on Tuesday, June 11th.
Shares of Bausch Health Companies stock opened at C$30.37 on Monday. The company has a current ratio of 1.21, a quick ratio of 0.73 and a debt-to-equity ratio of 906.29. The stock has a market capitalization of $10.74 billion and a price-to-earnings ratio of -11.64. Bausch Health Companies has a 1-year low of C$23.60 and a 1-year high of C$36.52. The firm’s 50-day moving average price is C$29.47 and its two-hundred day moving average price is C$31.23.
Bausch Health Companies (TSE:BHC) last issued its quarterly earnings data on Tuesday, August 6th. The company reported C$1.38 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of C$1.42 by C($0.04). The business had revenue of C$2.88 billion for the quarter, compared to analysts’ expectations of C$2.89 billion.
In other Bausch Health Companies news, Director Joseph Papa acquired 30,000 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The shares were acquired at an average cost of C$30.77 per share, for a total transaction of C$923,076.00. Following the completion of the acquisition, the director now directly owns 473,284 shares of the company’s stock, valued at approximately C$14,562,570.05. Also, Senior Officer William Douglas Humphries acquired 30,703 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average price of C$27.95 per share, for a total transaction of C$858,187.66. Following the completion of the acquisition, the insider now directly owns 89,220 shares of the company’s stock, valued at C$2,493,811.77.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.